Agents targeting TNF are widely used in the treatment of PsA, PsO, RA, spondyloarthropathies, and IBD and include infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol. The gene discussed is TNF; the disease is inflammatory bowel disease.